Group 1 - The core point of the article is that Beihai Kangcheng-B (01228) experienced a significant stock price increase, rising over 17% at one point and closing up 8.6% at HKD 3.03, with a trading volume of HKD 26.6484 million [1] - On February 16, Beihai Kangcheng announced a placement of 84.0336 million new shares to a wholly-owned subsidiary of WuXi Biologics, representing approximately 14.12% of the company's enlarged issued share capital, at a price of HKD 2.38 per share, which is a discount of about 14.7% compared to the closing price of HKD 2.79 on February 13 [1] - The net proceeds from the placement are expected to reach HKD 199 million, with approximately 60% allocated for settling the group's trade payables, around 28% for research and development expenses for existing product lines, and the remaining 12% for working capital and regulatory maintenance of commercialized products [1]
港股异动 | 北海康成-B(01228)一度涨超17% 折让14.7%配股筹2亿港元 药明生物持股升至16.27%